538 related articles for article (PubMed ID: 28292935)
21. Loss of expression of SMARCA4 (BRG1), SMARCA2 (BRM) and SMARCB1 (INI1) in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology.
Ramalingam P; Croce S; McCluggage WG
Histopathology; 2017 Feb; 70(3):359-366. PubMed ID: 27656868
[TBL] [Abstract][Full Text] [Related]
22. SMARCA4 inactivating mutations cause concomitant Coffin-Siris syndrome, microphthalmia and small-cell carcinoma of the ovary hypercalcaemic type.
Errichiello E; Mustafa N; Vetro A; Notarangelo LD; de Jonge H; Rinaldi B; Vergani D; Giglio SR; Morbini P; Zuffardi O
J Pathol; 2017 Sep; 243(1):9-15. PubMed ID: 28608987
[TBL] [Abstract][Full Text] [Related]
23. SMARCA4 (BRG1) loss of expression is a useful marker for the diagnosis of ovarian small cell carcinoma of the hypercalcemic type (ovarian rhabdoid tumor): a comprehensive analysis of 116 rare gynecologic tumors, 9 soft tissue tumors, and 9 melanomas.
Karanian-Philippe M; Velasco V; Longy M; Floquet A; Arnould L; Coindre JM; Le Naoures-Méar C; Averous G; Guyon F; MacGrogan G; Croce S
Am J Surg Pathol; 2015 Sep; 39(9):1197-205. PubMed ID: 26135561
[TBL] [Abstract][Full Text] [Related]
24. Cellular context determines DNA methylation profiles in SWI/SNF-deficient cancers of the gynecologic tract.
Kommoss FK; Tessier-Cloutier B; Witkowski L; Forgo E; Koelsche C; Köbel M; Foulkes WD; Lee CH; Kolin DL; von Deimling A; Howitt BE
J Pathol; 2022 Jun; 257(2):140-145. PubMed ID: 35218556
[TBL] [Abstract][Full Text] [Related]
25. Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
Connor YD; Miao D; Lin DI; Hayne C; Howitt BE; Dalrymple JL; DeLeonardis KR; Hacker MR; Esselen KM; Shea M
Gynecol Oncol; 2020 Apr; 157(1):106-114. PubMed ID: 31954538
[TBL] [Abstract][Full Text] [Related]
26. [SCCOHT/ovarian rhabdoid tumor: A case report].
Bourgoin R; Cornelis F; Masliah-Planchon J; Genestie C; Laé M
Ann Pathol; 2019 Sep; 39(5):357-363. PubMed ID: 30928254
[TBL] [Abstract][Full Text] [Related]
27. SWI/SNF complex-deficient soft tissue neoplasms: An update.
Schaefer IM; Hornick JL
Semin Diagn Pathol; 2021 May; 38(3):222-231. PubMed ID: 32646614
[TBL] [Abstract][Full Text] [Related]
28. Frequent co-inactivation of the SWI/SNF subunits SMARCB1, SMARCA2 and PBRM1 in malignant rhabdoid tumours.
Rao Q; Xia QY; Wang ZY; Li L; Shen Q; Shi SS; Wang X; Liu B; Wang YF; Shi QL; Ma HH; Lu ZF; He Y; Zhang RS; Yu B; Zhou XJ
Histopathology; 2015 Jul; 67(1):121-9. PubMed ID: 25496315
[TBL] [Abstract][Full Text] [Related]
29. Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation.
Tessier-Cloutier B; Kommoss FKF; Kolin DL; Němejcová K; Smith D; Pors J; Stewart CJR; McCluggage WG; Foulkes WD; von Deimling A; Köbel M; Lee CH
Mod Pathol; 2024 Jan; 37(1):100374. PubMed ID: 37925057
[TBL] [Abstract][Full Text] [Related]
30. Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer.
Leitner K; Tsibulak I; Wieser V; Knoll K; Reimer D; Marth C; Fiegl H; Zeimet AG
Sci Rep; 2020 Nov; 10(1):20412. PubMed ID: 33230143
[TBL] [Abstract][Full Text] [Related]
31. [Small cell carcinoma of ovary, hypercalcemic type: analysis of clinicopathologic characteristics and the diagnostic utility of loss expression of SMARCA4 protein].
Wang L; Tan C; Tu X; Zhang Y; Li X; Chang B
Zhonghua Bing Li Xue Za Zhi; 2015 Dec; 44(12):859-63. PubMed ID: 26888501
[TBL] [Abstract][Full Text] [Related]
32. Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.
Lang JD; Hendricks WPD; Orlando KA; Yin H; Kiefer J; Ramos P; Sharma R; Pirrotte P; Raupach EA; Sereduk C; Tang N; Liang WS; Washington M; Facista SJ; Zismann VL; Cousins EM; Major MB; Wang Y; Karnezis AN; Sekulic A; Hass R; Vanderhyden BC; Nair P; Weissman BE; Huntsman DG; Trent JM
Clin Cancer Res; 2018 Apr; 24(8):1932-1943. PubMed ID: 29440177
[No Abstract] [Full Text] [Related]
33. Small-Cell Carcinoma of the Ovary, Hypercalcemic Type-Genetics, New Treatment Targets, and Current Management Guidelines.
Tischkowitz M; Huang S; Banerjee S; Hague J; Hendricks WPD; Huntsman DG; Lang JD; Orlando KA; Oza AM; Pautier P; Ray-Coquard I; Trent JM; Witcher M; Witkowski L; McCluggage WG; Levine DA; Foulkes WD; Weissman BE
Clin Cancer Res; 2020 Aug; 26(15):3908-3917. PubMed ID: 32156746
[TBL] [Abstract][Full Text] [Related]
34. The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
Vangamudi B; Paul TA; Shah PK; Kost-Alimova M; Nottebaum L; Shi X; Zhan Y; Leo E; Mahadeshwar HS; Protopopov A; Futreal A; Tieu TN; Peoples M; Heffernan TP; Marszalek JR; Toniatti C; Petrocchi A; Verhelle D; Owen DR; Draetta G; Jones P; Palmer WS; Sharma S; Andersen JN
Cancer Res; 2015 Sep; 75(18):3865-3878. PubMed ID: 26139243
[TBL] [Abstract][Full Text] [Related]
35. SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2.
Kim KH; Kim W; Howard TP; Vazquez F; Tsherniak A; Wu JN; Wang W; Haswell JR; Walensky LD; Hahn WC; Orkin SH; Roberts CW
Nat Med; 2015 Dec; 21(12):1491-6. PubMed ID: 26552009
[TBL] [Abstract][Full Text] [Related]
36. The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases.
Witkowski L; Donini N; Byler-Dann R; Knost JA; Albrecht S; Berchuck A; McCluggage WG; Hasselblatt M; Foulkes WD
Fam Cancer; 2017 Jul; 16(3):395-399. PubMed ID: 27866340
[TBL] [Abstract][Full Text] [Related]
37. Loss of SMARCA4 Expression Is Both Sensitive and Specific for the Diagnosis of Small Cell Carcinoma of Ovary, Hypercalcemic Type.
Conlon N; Silva A; Guerra E; Jelinic P; Schlappe BA; Olvera N; Mueller JJ; Tornos C; Jungbluth AA; Young RH; Oliva E; Levine D; Soslow RA
Am J Surg Pathol; 2016 Mar; 40(3):395-403. PubMed ID: 26645725
[TBL] [Abstract][Full Text] [Related]
38. SWI/SNF protein and claudin-4 expression in anaplastic carcinomas arising in mucinous tumours of the ovary and retroperitoneum.
Chaudet K; Kem M; Lerwill M; Young RH; Mino-Kenudson M; Agaimy A; McCluggage WG; Oliva E
Histopathology; 2020 Aug; 77(2):231-239. PubMed ID: 32268438
[TBL] [Abstract][Full Text] [Related]
39. CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary.
Xue Y; Meehan B; Macdonald E; Venneti S; Wang XQD; Witkowski L; Jelinic P; Kong T; Martinez D; Morin G; Firlit M; Abedini A; Johnson RM; Cencic R; Patibandla J; Chen H; Papadakis AI; Auguste A; de Rink I; Kerkhoven RM; Bertos N; Gotlieb WH; Clarke BA; Leary A; Witcher M; Guiot MC; Pelletier J; Dostie J; Park M; Judkins AR; Hass R; Levine DA; Rak J; Vanderhyden B; Foulkes WD; Huang S
Nat Commun; 2019 Feb; 10(1):558. PubMed ID: 30718512
[TBL] [Abstract][Full Text] [Related]
40. NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition.
Drosos Y; Myers JA; Xu B; Mathias KM; Beane EC; Radko-Juettner S; Mobley RJ; Larsen ME; Piccioni F; Ma X; Low J; Hansen BS; Peters ST; Bhanu NV; Dhanda SK; Chen T; Upadhyaya SA; Pruett-Miller SM; Root DE; Garcia BA; Partridge JF; Roberts CWM
Mol Cell; 2022 Jul; 82(13):2472-2489.e8. PubMed ID: 35537449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
